BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34289231)

  • 1. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
    Buelens S; Poelaert F; Claeys T; De Bleser E; Dhondt B; Verla W; Ost P; Rappe B; De Troyer B; Verbaeys C; Kimpe B; Billiet I; Plancke H; Fransis K; Willemen P; Ameye F; Decaestecker K; Lumen N
    BJU Int; 2022 Jun; 129(6):699-707. PubMed ID: 34289231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial.
    Poelaert F; Verbaeys C; Rappe B; Kimpe B; Billiet I; Plancke H; Decaestecker K; Fonteyne V; Buelens S; Lumen N
    Urology; 2017 Aug; 106():146-152. PubMed ID: 28435034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
    Heidenreich A; Pfister D; Porres D
    J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
    Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
    BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
    Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
    Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
    Heidenreich A; Pfister D; Brehmer B; Porres D
    Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Trelles CR; Martinez-Piñeiro L
    Eur Urol; 2021 Dec; 80(6):764-765. PubMed ID: 34579999
    [No Abstract]   [Full Text] [Related]  

  • 9. Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.
    Steuber T; Berg KD; Røder MA; Brasso K; Iversen P; Huland H; Tiebel A; Schlomm T; Haese A; Salomon G; Budäus L; Tilki D; Heinzer H; Graefen M; Mandel P
    Eur Urol Focus; 2017 Dec; 3(6):646-649. PubMed ID: 28753877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
    Rajwa P; Zattoni F; Maggi M; Marra G; Kroyer P; Shariat SF; Briganti A; Montorsi F; Heidegger I; Gandaglia G;
    Eur Urol Focus; 2023 Jul; 9(4):637-641. PubMed ID: 36697321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.
    Makino K; Nakagawa T; Ito E; Kasahara I; Murata T; Fujimura T; Fukuhara H; Homma Y
    Jpn J Clin Oncol; 2018 May; 48(5):485-490. PubMed ID: 29635526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Patel DN; Jha S; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Chapin BF; Freedland SJ
    Int J Urol; 2018 Dec; 25(12):998-1004. PubMed ID: 30253446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Lumen N; De Bleser E; Buelens S; Verla W; Poelaert F; Claeys W; Fonteyne V; Verbeke S; Villeirs G; De Man K; Rottey S; Van Praet C; Decaestecker K; Ost P;
    Eur Urol Open Sci; 2021 Jul; 29():68-76. PubMed ID: 34337536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.
    Sooriakumaran P; Wilson C; Rombach I; Hassanali N; Aning J; D Lamb A; Cathcart P; Eden C; Ahmad I; Rajan P; Sridhar A; Bryant RJ; Elhage O; Cook J; Leung H; Soomro N; Kelly J; Nathan S; Donovan JL; Hamdy FC
    BJU Int; 2022 Jul; 130(1):43-53. PubMed ID: 34878715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of radical prostatectomy in metastatic prostate cancer: A review.
    Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
    Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Hackman G; Taari K; Tammela TL; Matikainen M; Kouri M; Joensuu T; Luukkaala T; Salonen A; Isotalo T; Pétas A; Hendolin N; Boström PJ; Aaltomaa S; Lehtoranta K; Hellström P; Riikonen J; Korpela M; Minn H; Kellokumpu-Lehtinen PL; Pukkala E; Hemminki A;
    Eur Urol; 2019 Nov; 76(5):586-595. PubMed ID: 31375279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease.
    Heidenreich A; Pfister D
    Curr Opin Urol; 2020 Jan; 30(1):90-97. PubMed ID: 31724996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience with cytoreductive radical prostatectomy in patients with oligometastatic prostate cancer].
    Berczi C; Dócs J; Flaskó T
    Orv Hetil; 2021 Mar; 162(13):483-487. PubMed ID: 33774598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
    Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
    Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.